Figure 6

3-MA inhibits late-phase IκBα degradation. (A–D) HUVECs were pretreated with or without 5 mmol/L 3-MA for 30 min followed by 10 ng/mL TNFα (A,C) or 10 ng/mL IL-1β (B,D) for indicated time. IκBα, IκBβ and IκBε were analyzed by western blotting. (E,F) IκBα blots of TNFα or IL-1β control vs. 3-MA or MG-132 treatment (n = 3) at each time point were quantified by densitometry. (G) HUVECs were transfected with siRNA for 72 h followed by 10 ng/mL IL-1β or 10 ng/mL TNFα for 6 h. IκBα, IκBβ, IκBε and Atg5 were analyzed by western blotting.